The "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)" formulated by the National Health Commission was issued on December 22, 2020, and the measures will be implemented from March 1, 2021. At the same time, to further standardize the clinical application of new anti-tumor drugs, the National Health Commission’s Expert Committee on Rational Drug Use took the lead in revising and improving the "Guiding Principles for the Clinical Application of New Anti-tumor Drugs (2019 Edition)", which was issued on December 29, 2020.
To help implement the National Health Commission's requirements for the management of anti-tumor drugs at all levels of medical institutions, ensure the rational use of drugs, and improve the level of comprehensive clinical tumor management, the public welfare project was launched. The project was initiated by the Expert Committee on Anti-tumor Drug Safety Management of Chinese Society of Clinical Oncology and Beijing Hisco Clinical Oncology Research Foundation, co-organized by Jiangsu Hengrui Pharmaceutical Co., Ltd., and lectured by committee members and other clinical experts, aiming to improve doctors The level of clinical application of anti-tumor drugs guarantees medical quality and medical safety, and benefits more cancer patients. We sincerely invite your participation!
Comments
Post a Comment